Navigation Links
Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)

NASHVILLE, Tenn., May 18 /PRNewswire/ -- Cumberland Pharmaceuticals announced today the launch of an online in-service program for hospitals using Acetadote (acetylcysteine) Injection, the company's intravenous treatment for acetaminophen overdose.

(Photo: )

Available at, the webcast provides hospital pharmacists and physicians, educators and other healthcare providers with information and guidelines on dosage and administration of Acetadote for treatment of acetaminophen poisoning. The webcast is designed to supplement and reinforce information provided by Cumberland's hospital sales force through convenient, anytime access to training. This online program will also provide detailed training to hospitals where personal in-service visits by a Cumberland representative are not readily available.

"We are pleased to offer this additional level of support for healthcare providers using our product," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "Acetadote is a potentially life-saving drug, and as use of the product continues to rise we believe it is important to provide healthcare professionals with as much information as possible to facilitate proper administration."

About Acetadote

Acetadote is used in the emergency department and hospital inpatient setting to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter and prescription medications. It is the only approved injectable product in the United States for the treatment of acetaminophen overdose, the leading cause of toxic drug ingestions reported to U.S. poison control centers(1).

Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma, or where there is a history of bronchospasm. The total volume administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure, and death.

Please visit for the full prescribing information.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company that develops and markets niche pharmaceutical products for specific physician segments, including hospital acute care and gastroenterology. Cumberland is dedicated to providing high-quality products which fill unmet medical needs. For more information, please visit the Cumberland Pharmaceuticals web site at

Forward-Looking Statements

This release contains forward-looking statements which reflect management's current views of future events and operations. Forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from these statements. Cumberland does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

(1) National Poison Data System, American Association of Poison Control Centers

Acetadote(R) is a registered trademark of Cumberland Pharmaceuticals Inc.

SOURCE Cumberland Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):